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AbstrACt 
Introduction The initial treatment for high-risk non-
muscle invasive bladder cancer (NMIBC) is endoscopic 
resection of the tumour followed by BCG therapy. In 
those who develop recurrence, the standard treatment is 
radical cystectomy. Despite the advancement in surgical 
technique and postoperative care, the degree of morbidity 
associated with radical cystectomy remains high, therefore 
less invasive treatment modalities are desirable. Therapies 
targeting the programmed death (PD) pathway have shown 
promise in urothelial carcinoma. We undertook the current 
study to determine the safety and efficacy of administering 
pembrolizumab (a monoclonal antibody targeting the 
interaction between PD-1 and its ligand) in combination with 
BCG in high-risk NMIBC.
Methods This is a single-centre phase I safety and 
efficacy study of pembrolizumab used in combination with 
intravesicular BCG treatment for subjects with pathologically 
documented high-risk NMIBC despite having received two 
courses of induction therapy or BCG treatment followed by 
maintenance BCG. Fifteen subjects will be enrolled, patients 
will receive treatment with 200 mg of pembrolizumab 
every 21 days, starting 2 weeks from the initial endoscopic 
resection and continuing for 6 weeks after the final dose 
of BCG. The primary objective is to determine the safety of 
administering pembrolizumab at a fixed dose of 200 mg 
every 3 weeks in conjunction with intravesicular BCG 
treatment in patients with high-risk NMIBC who have failed 
previous treatment. Secondary objectives are to determine 
the 19 weeks and the 3, 12 and 24 months post-treatment 
completion complete response rate with combined 
pembrolizumab and intravesicular BCG therapy in the 
aforementioned patients.
Ethics and dissemination The study has been approved 
by the Institutional Review Board of the Henry Ford Hospital. 
The results of this study will be published in a peer-reviewed 
journal and presented at a scientific conference.
trial registration number NCT02324582.
IntroduCtIon
Bladder cancer is the fifth most common 
cancer in the USA.1 The standard of care 
for patients who have high-risk non-muscle 
invasive bladder cancer (NMIBC) at presenta-
tion is a combination of endoscopic resection 
and intravesicular BCG instillation. However, 
only two-thirds of patients respond to BCG, 
while the remaining one-third experience 
recurrent disease, which is associated with a 
poorer prognosis.2 3 Given that the only other 
accepted treatment for recurrent high-risk 
NMIBC is a radical cystectomy, a surgery asso-
ciated with high morbidity, identification of 
agents active against this disease process is 
clearly warranted.4 
The blockade of the immune checkpoint 
pathway involving programmed death 1 
(PD-1) receptor and its ligands, CD274 
(PD-L1) and CD273 (PD-L2), has been 
recently shown to be effective in the treatment 
of various cancers including urothelial carci-
noma (UC).5 6 Previous studies have identi-
fied that the expression of PD-L1 has been 
linked to higher grade disease, and PD-L1 
expression has been found to be extremely 
abundant in BCG-induced bladder granulo-
mata in patients failing BCG treatment.7 We 
strengths and limitations of this study
 ► One of the first clinical trials to assess the safety and 
efficacy of programmed death (PD)-1 inhibitors in 
combination with BCG for patients with non-muscle 
invasive high-risk urothelial carcinoma of the blad-
der after having failed two courses of BCG induction 
therapy or BCG induction followed by maintenance 
therapy.
 ► Study provides extensive follow-up and multiple ob-
jective measures assessing the safety and efficacy 
of PD-1 inhibitors.
 ► This study is non-randomised and unblinded.
 ► Long-term enrolment and frequent clinical obliga-
tions may result in failure of retention of subjects.
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hypothesise that a combination of pembrolizumab, also 
known as MK-3475, as it is labelled throughout the study 
protocol, and BCG following endoscopic treatment of 
high-risk NMIBC may be effective in improving outcomes 
of NMIBC after endoscopic treatment in patients unfit or 
unwilling to be treated with radical cystectomy. The aim 
of this study is to determine the safety and response of 
administering pembrolizumab (a monoclonal antibody 
designed to block the interaction between PD-1 and its 
ligand) in conjunction with BCG treatment in patients 
with high-risk NMIBC. In this paper, we report the treat-
ment protocol for the study.
MEthods And AnAlysIs
rationale
PD-1 is an inhibitory cell-surface receptor that can be 
stimulated to be expressed on T cells, B cells, natural 
killer (NK) T cells, monocytes and dendritic cells (DC).8 
PD-L1 is widely expressed by haematopoietic, non-haema-
topoietic and tumour cells, whereas PD-L2 is expressed 
mainly by DCs and macrophages.9 10 Higher expression 
of PD-L1 in cancers is associated with poor survival as 
tumours can evade the immune system by stimulating 
PD-1.11 12 PD-L1 expression, a marker for response to 
anti-PD-1 agents, is observed in 7% of pTa, 16% of pT1% 
and 45% of carcinoma in situ (CIS) urothelial tumours.7 
PD-L1 expression in these tumours is also associated 
with high-grade disease. In addition, PD-L1 expression 
is found to be extremely abundant in the BCG-induced 
transitional epithelium granulomata in patients failing 
BCG treatment.13 Recent pharmacokinetic (PK) studies 
showing efficacy of anti-PD-1 agents in advanced bladder 
cancer, advanced melanoma and other cancers support 
combining these agents with BCG treatment in patients 
with high-risk superficial bladder cancer to provide these 
patients with an alternative to radical cystectomy if they 
fail BCG alone. Previous experience with immunological 
response supports dosing patients with anti-PD-1 agents 
2–3 weeks before BCG treatment, which would allow the 
bladder to be primed for BCG with the hopes of a greater 
proportion of complete responses to BCG.13 In recent 
years, pembrolizumab has been investigated, in conjunc-
tion with various other chemotherapeutic agents and 
immunotherapy, in non-metastatic bladder cancer, meta-
static bladder cancer and upper tract UC. Based on these 
data and promising preliminary results, a combination of 
pembrolizumab with BCG may be effective in preventing 
recurrence of NMIBC after previously failed treatment.
trial blinding
This is an open-label trial; therefore, the sponsor, investi-
gator and subject will know the treatment administered.
study design
This is a single-centre phase I safety and efficacy study 
of pembrolizumab therapy used in combination with 
bladder infused BCG treatment for subjects, 18 years or 
older, with pathologically documented high-risk NMIBC 
despite having received two courses of BCG induction 
therapy or BCG induction followed by maintenance BCG. 
Subjects will have confirmation of NMIBC. Approximately 
20 subjects will be screened to treat 15 eligible subjects. 
Subjects will be enrolled to a single treatment group of a 
fixed dose of MK-3475 and BCG (figure 1).
trial schedule
Trial schedule (figure 2) summarises the trial procedures 
to be performed at each visit. It may be necessary to 
perform these procedures at unscheduled time points if 
deemed clinically necessary by the investigator. Further-
more, additional evaluations/testing may be deemed 
Figure 1 Trial design for phase I study of pembrolizumab in 
combination with Bacillus Calmette-Guérin for patients with 
high risk non-muscle invasive bladder cancer. CIS, carcinoma  
in situ; IFN, interferon.
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Figure 2 Trial schedule for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with 
high risk non-muscle invasive bladder cancer. *Screening visit: No study required procedures should be conducted (unless 
part of routine care) prior to the signing of the informed consent document. Screening visit laboratory procedures may be used 
for day 1 of cycle 1 if completed within 10 days of day 1 of cycle 1. †Early discontinuation visit: all subjects who discontinue 
treatment early for any reason should undergo all procedures listed in the flow chart for discontinuation visit. ‡If a subject has 
completed all study treatment, the subject should complete the 30-day safety follow-up visit procedures listed in the flow 
chart. §Follow-up visits should occur at approximately 3, 6, 9, 12, 18 and 24 months from week 19 cystoscopy. It is expected 
that follow-up data will be collected from routine office visits, which generally occur every 3 months in this population. There 
may be a shift in schedules if the participant has been given maintenance therapy or was found to have a recurrence. Subject 
will complete a final set of questionnaires at the 3 month visit. Follow-up information may be collected via medical record 
and document review only. However, patient contact via phone or in person may occur if information is not available via chart 
review. **Subject identification card may be given at any time after consent process has occurred and prior to treatment on day 
1 of cycle 1. ††Prior and concomitant medications will include any medications taken within the 28 days prior to consent and 
through the safety visit and will include prescribed, over-the-counter and herbal/alternative remedies. ‡‡Poststudy treatment 
anticancer therapy and recurrence status may be collected through follow-up chart review. §§Questionnaires: American Urologic 
Association Symptoms Index, International prostate symptom score (IPSS) and Quality of Life will be completed prior to any 
treatment or procedures scheduled for that visit. ***Transurethral resections: all TUBR will occur as part of SOC and as clinically 
indicated. †††Adverse events will be collected from time of main study informed consent through 30 days post last study drug 
infusion/treatment. ‡‡‡Physical exam: full physical exams are required at screening and at the 30-day follow-up. All other exams 
may be symptom directed. §§§Performance status: Eastern cooperative group (ECOG) performance status scale should be used 
to measure performance status. ****ECG, chest X-ray and pulmonary function tests will be completed prior to day 1 of cycle 1 
and will only be repeated as clinically indicated. ††††Prothromin time (PT)/International normalization ratio (INR) and Acticatved 
prothrombin time (aPTT) will be completed prior to all resections/possibly biopsies as standard of care. All other monitoring 
of PT/INR and aPTT will only be completed as clinically indicated (ie, if on coumadin). ‡‡‡‡Cystoscopy will be performed as 
standard of care but will be considered measures for efficacy. Biopsy will be performed as clinically indicated. §§§§Specimen 
collection/correlative studies: whole blood, serum and urine will be collected at time of consent or may be collected at any time 
prior to treatment on day 1 of cycle 1. Specimens for correlative study will also occur at each visit through week 19, repeat 
cystoscopy (12 visits). Saliva will be collected only at baseline. Tumour tissue will only be collected at week 19 biopsy if a 
biopsy is clinically indicated at the time of cystoscopy. Specimen collection is requested at 3, 6, 9, 12, 18 and 24 months follow-
up visits if subject is being treated locally at the site, although not required. Tissue will only be collected if a biopsy is clinically 
indicated at time of cystoscopy.
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necessary by the sponsor for reasons related to subject 
safety. In some cases, such evaluation/testing may be 
potentially sensitive in nature (eg, HIV, hepatitis C, etc), 
and thus local regulations may require that additional 
informed consent be obtained from the subject. In these 
cases, such evaluations/testing will be performed in 
accordance with those regulations.
Patient selection
Subjects, who meet required inclusion and exclusion 
criteria are eligible for enrolment into the study (figure 3 
and figure 4).
trial treatment dosage, formulation, preparation and 
frequency
BCG: the rationale for the use of the indicated dose of 
BCG is based on Food and Drug Administration (FDA)-ap-
proved and commercially provided product. Dosing for 
the intraluminal treatment of CIS and for the prophy-
laxis of recurrent papillary tumours consists of one phial 
of BCG suspended in 50 mL preservative-free saline. The 
preparation of the BCG suspension will be completed 
using aseptic technique and according to FDA-approved 
labelling and use information. Patients may have treat-
ment with more than one phial to ensure treatment of 
all tumour sites. BCG treatment will be administered 
beginning on day 1 of cycle 3 (week 7) of pembrolizumab 
after all procedures/assessments have been completed as 
detailed on the trial flow chart. BCG treatment will be 
repeated every 7 days at weeks 8, 9, 10, 11 and 12. BCG 
treatment may be administered up to 1 day before or 
after the scheduled date (at 7 days) due to administrative 
reasons. All trial treatments will be administered on an 
outpatient basis and according to institutional standards. 
BCG dose modification has been shown to reduce effi-
cacy; therefore, no dose modifications will be attempted 
in this trial. The dose, frequency, route of administration 
and duration are summarised in figure 5.
BCG treatment will be withheld for grade 2 haema-
turia, grade 1 fever and drug-related grade 4 haematolog-
ical toxicities, and all other non-haematological toxicity 
Figure 3 Subject inclusion criteria for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for 
patients with high risk non-muscle invasive bladder cancer. CIS, carcinoma in situ. 
copyright.
 o
n
 D
ecem
ber 6, 2019 at Henry Ford Hospital. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028287 on 17 July 2019. Downloaded from 
5Jamil ML, et al. BMJ Open 2019;9:e028287. doi:10.1136/bmjopen-2018-028287
Open access
grade ≥3 adverse effects (AEs) including laboratory 
abnormalities and severe or life-threatening AEs. Treat-
ment will be postponed until resolution of febrile illness, 
urinary tract infection or gross haematuria and AE resolu-
tion to grade <1. In the event of a grade 1 or 2 immune-re-
lated adverse event requiring corticosteroid treatment, 
BCG treatment may be delayed for up to 2 weeks with the 
expectation that steroid treatment will be discontinued 
prior to the next BCG treatment cycle. A delay of longer 
than 2 weeks will permanently discontinue the patient 
from BCG treatment within the study or permanent 
withdrawal of the patient from the study. The choice will 
be at the discretion of the treating investigator. Steroid 
treatment for grade 3 or higher immune-mediated events 
will require discontinuation of BCG treatment and/or 
withdrawal from the study.
Pembrolizumab
A fixed dose of 100 mg pembrolizumab will be adminis-
tered intravenously on day 1 of a 21-day cycle for up to 
six cycles for the first three subjects. If one subject of 
the initial three requires the dose of pembrolizumab to 
be withheld or discontinued, the 100 mg cohort will be 
expanded to six subjects. If two out of three or three out 
of six subjects develop toxicity that requires the dose to be 
withheld or discontinued, the dose will not be escalated 
Figure 4 Subject exclusion criteria for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for 
patients with high risk non-muscle invasive bladder cancer. *Chest X-ray, CT urogram or MRI and urogram are allowed to 
ascertain the superficial nature of the disease when indicated, but not required. If urogram protocol is not available or contrast 
allergy/poor renal function precludes such imaging, then non-contrast CT or MRI of the abdomen/pelvis within 90 days of study 
entry will suffice. †Exceptions include upper urinary tract transitional cell cracinoma (TCC), basal cell carcinoma of the skin, 
squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy. ‡Use of disease-
modifying agents, corticosteroids or immunosuppressive drugs. Replacement therapy (eg, thyroxine, insulin or physiologic 
corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment. PD, 
programmed death.
copyright.
 o
n
 D
ecem
ber 6, 2019 at Henry Ford Hospital. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028287 on 17 July 2019. Downloaded from 
6 Jamil ML, et al. BMJ Open 2019;9:e028287. doi:10.1136/bmjopen-2018-028287
Open access 
to 200 mg pembrolizumab every 3 weeks. All remaining 
subjects will be treated at 100 mg pembrolizumab every 
3 weeks for six cycles. This is based on multiple clinical 
trials which have also used pembrolizumab at the afore-
mentioned dose.14 An open-label phase I trial (PN001) 
in subjects with melanoma was conducted to evaluate the 
safety and clinical activity of single agent pembrolizumab. 
The dose escalation portion of this trial evaluated three 
dose levels, 1, 3 and 10 mg/kg, administered every 2 weeks 
in subjects with advanced solid tumours. All three dose 
levels were well tolerated, and no dose-limiting toxicities 
were observed.14 This first-in-human study of pembroli-
zumab showed evidence of target engagement and objec-
tive evidence of tumour size reduction at all dose levels (1, 
3 and 10 mg/kg every 2 weeks). No maximum tolerated 
dose was identified.14 Selection of 200 mg as the appro-
priate dose for a switch to fixed dosing is based on simula-
tion results indicating that 200 mg will provide exposures 
that are reasonably consistent with those obtained with 
2 mg/kg dose and importantly will maintain individual 
patient exposures within the exposure range estab-
lished in melanoma as associated with maximal clinical 
response. A population PK model, which characterised 
the influence of body weight and other patient covari-
ates on exposure, has been developed using available 
data from 476 subjects from PN001. The distribution of 
exposures from the 200 mg fixed dose are predicted to 
considerably overlap those obtained with the 2 mg/kg 
dose, with some tendency for individual values to range 
slightly higher with the 200 mg fixed dose. The slight 
increase in PK variability predicted for the fixed dose rela-
tive to weight-based dosing is not expected to be clinically 
important given that the range of individual exposures 
is well contained within the range of exposures shown 
in the melanoma studies of 2 and 10 mg/kg to provide 
similar efficacy and safety.
Trial treatment will be administered on day 1 of 
each cycle after all procedures/assessments have been 
completed as detailed on the trial flow chart. Trial treat-
ment may be administered up to 3 days before or after 
the scheduled day 1 of each cycle due to administrative 
reasons. Adverse events (both non-serious and serious) 
associated with pembrolizumab exposure may represent 
an immunological aetiology. These adverse events may 
occur shortly after the first dose or several months after 
the last dose of treatment. Pembrolizumab must be with-
held for drug-related toxicities and severe or life-threat-
ening AEs. Known and theoretical risks of pembrolizumab 
are documented within the original study protocol and 
management of said risks and AEs is also noted within the 
original study protocol.
objectives
Primary objective
To determine the safety of administering pembrolizumab 
at a fixed dose of 200 mg every 3 weeks in conjunction 
with intravesicular BCG treatment in patients with high-
risk NMIBC who have failed two courses of induction 
therapy or one course of BCG induction therapy followed 
by maintenance therapy.
Secondary objective
To determine the 19 weeks and the 3, 12 and 24 months 
post-treatment completion complete response rate 
with combined pembrolizumab and intravesicular BCG 
therapy for patients with non-muscle invasive superficial 
bladder cancer who have failed two courses of induction 
therapy or one course of BCG induction therapy followed 
by maintenance therapy
Exploratory objectives
Three objectives are to examine pretreatment and 
post-treatment (MK-3475/BCG) bladder biopsy speci-
mens for PD-1, PD-L1 and CD3; to examine the whole 
exome sequencing of subjects’ germline DNA and forma-
lin-fixed paraffin-embedded tissue and to analyse blood 
and urine specimens from enrollees for potential devel-
opment of blood and urine assays for determination of 
response to treatment.
Adverse effects
The investigator or qualified designee will assess each 
subject to evaluate for potential new or worsening AEs 
as specified in the detailed trial schedule and more 
frequently, if clinically indicated. Adverse experiences will 
be graded and recorded throughout the study and during 
the follow-up period according to the National Cancer 
Figure 5 Trial treatment for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with 
high risk non-muscle invasive bladder cancer. *The first three subjects will be dosed at 100 mg. If the Data Safety Review 
Team approves, the dose will be escalated to 200 mg when the fourth subject is enrolled. †The MK-3475 dosing interval may 
be increased due to toxicity. BCG treatment may be interrupted or delayed as per the instructions for use supplied with BCG. 
‡BCG: one phial of BCG suspended in 50 mL preservative-free saline.
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Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) V.4.0. Toxicities will be character-
ised in terms of seriousness, causality, toxicity grading 
and action taken with regard to trial treatment. AEs will 
be recorded from the time the subject signs the consent 
through 30 days post the last study treatment. All AEs of 
unknown aetiology associated with pembrolizumab expo-
sure should be evaluated to determine if it is possibly an 
event of clinical interest of a potentially immunological 
aetiology.
All known and theoretical risks and AEs of BCG and 
pembrolizumab are documented within the original 
study protocol for reference. Potential AEs and risks are 
to be monitored for during each mandatory clinical visit. 
All of the known and theoretical risks and AEs of BCG 
and pembrolizumab are to be managed by the investiga-
tional team and all other necessary support staff. Manage-
ment of the aforementioned risks and AEs is documented 
within the original study protocol.
Parameters for determination of patient safety and for 
trial suspension and discontinuation are noted within 
the original study protocol. As per the original study 
protocol, section 5.2.3.3 table 3, all grade 4 toxicities 
result in permanent discontinuation from the study. 
Further details and exceptions are noted within the orig-
inal study protocol. As noted in section 5.8 of the original 
study protocol, if there are any fatal treatment toxicities 
or if one or more of the 15 subjects treated experience a 
grade 4 toxicity, subject accrual will be suspended and all 
data pertaining to the events will be reviewed by the Study 
Investigators and Data Safety Review Team to determine 
if there is the need for any corrective actions. Following 
review and appropriate action by the investigating team, 
subject accrual may recommence. If there is a second 
fatal treatment/morbidity event related to the study treat-
ment or procedures, the study will be terminated. If 4 
of 15 subjects experience grade 4 toxicities, the accrual 
will be suspended and reviewed for added appropriate 
measures. If five subjects experience grade 4 toxicity, the 
study will be terminated.
statistical measures and analysis
This protocol aims at assessing the activity of one treat-
ment arm, BCG in combination with pembrolizumab in 
patients with NMIBC. We would like to detect an activity 
which is at least 25% greater than that of historical 
controls (50%) from case series of BCG-only treatment.
Sample size calculation for this protocol is based on the 
work by Kahn et al.15 Using a one-stage design, 15 patients 
will be enrolled in this study. Patient-related data will be 
collected and transferred to an excel spreadsheet for 
statistical analysis. SAS software V.9.4 will be used for all 
data analysis. Descriptive statistics will be computed for 
all study variables. Continuous variables will be described 
with measures of central tendency (mean, median) and 
dispersion (range, SD). Categorical variables will be 
summarised as frequencies and percentages. Some exam-
ples include tumour stage (Ta, T1, CIS), age, Eastern 
cooperative group (ECOG) performance status scale (0, 
1, 2), sex and use of tobacco and alcohol.
For primary objective, the proportion of patients with 
each AE will be reported along with the NCI CTCAE 
grade of the AE (V.4.0). The Quality of Life Question-
naire, which includes one question with seven categor-
ical responses, will be described with frequencies and 
percentages. The American Urologic Association Symp-
toms Index Questionnaire, which includes seven ques-
tions each with a numerical score between 0 and 5 as well 
as a final numerical sum of all responses, will be described 
with measures of central tendency and dispersion. Due 
to the questionnaires being given at three time points 
(pretreatment, mid-treatment and post-treatment), the 
responses may be analysed to look for longitudinal effects 
over time for specific variables of interest with repeated 
measures analysis of variance to evaluate changes and 
control for individual differences (although this would 
be very low power due to n=15).
For the secondary objective, subjects will be assessed at 
19 weeks, 3, 12 and 24 months post-treatment comple-
tion for complete response. The outcome end point will 
be complete response status at 19 weeks, 3, 12 and 24 
months post-treatment to measure complete response, 
recorded as yes or no and summarised as proportions and 
a per cent.
For the exploratory objectives, Pearson’s or Spearman’s 
rank correlation coefficient will be used to estimate 
correlations between expression level change and treat-
ment outcome, as well as the correlations between muta-
tion presence and treatment outcome.
Patient and public involvement
Patient and the public were not involved in the design, 
recruitment and conduction of the present study. Results 
of the study will be disseminated to the study participants 
on request. Patient advisors were not used in the conduc-
tion of this study.
EthICs, ConfIdEntIAlIty And rEgulAtory dEtAIls
The investigator and sponsor of the study will adhere to all 
applicable data privacy and confidentiality laws and regu-
lations (ie, Health inurance portability and accountability 
act (HIPAA)). Those applicable include institutional, 
state and federal law. It is the responsibility of the inves-
tigator and sponsor to ensure the subject data as well as 
sensitive study information is handled according to appli-
cable guidelines and laws. Appropriate authorisation and 
consent for use, disclosure or transfer of protected health 
information must be obtained.
Subjects’ names will not be recorded on the case report 
forms (CRF). Only the subject number and subject’s 
initials will be recorded, where permitted. If the subject’s 
name appears on any other document (eg, pathology 
report), it must be obliterated on the copy of the docu-
ment as appropriate. Study data stored on a computer 
will be stored in accordance with local data protection 
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laws. The subjects will be informed that representatives 
of the sponsor or its designee, institutional review board 
and regulatory authorities may inspect their medical 
records to verify the information collected, and that all 
personal information made available for inspection will 
be handled in strictest confidence and in accordance with 
local data protection laws.
Qualified staff of the sponsor will monitor the study 
according to a pre-arranged monitoring plan. Monitoring 
of the study will include:
 ► Evaluation of study progress.
 ► Verification of CRF accuracy and completeness.
 ► Resolution of inconsistencies in study records.
 ► Assurance of protocol requirements and investigator’s 
obligations are fulfilled.
 ► Assurance of compliance with applicable laws and 
regulations.
Study monitors will periodically review all CRFs and 
supporting source documentation of participating 
subjects. The CRFs and supporting documentation must 
remain up to date and available to the study monitor 
as arranged. CRF data entry will be verified to corre-
spond with source documentation (laboratory, imaging, 
pathology reports, etc) and reviewed for completeness. 
Data discrepancies will be identified and reported to the 
investigator and site staff.
Protocol deviations will be identified and recorded on 
a deviation log.
This submission was drafted under the use of the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials reporting guidelines.16
dIsCussIon
This open-label, single-centre, phase I treatment trial 
intends to investigate the safety and efficacy of pembroli-
zumab in combination with intravesicular BCG. As previ-
ously mentioned, the optimal alternative to management 
of patients unfit or unwilling to undergo radical cystec-
tomy remains unknown. This prospective clinical trial 
attempts to provide a more definitive treatment option 
for NMIBC refractory to BCG. This study uses previously 
established treatment modalities with available immuno-
therapeutic agents.
The design of the present study will allow the researchers 
to discern the safety and efficacy of pembrolizumab and 
BCG as a viable option for NMIBC. It has been well docu-
mented that although radical cystectomy provides defin-
itive cancer control in NMIBC, the associated morbidity 
and mortality continues to remain high.4 A non-surgical 
option following BCG failure is desirable. Various studies 
have demonstrated promising results in regard to the effi-
cacy of agents such as pembrolizumab and it is presumed 
that this trend will continue with increased investigation 
and utilisation. It has been previously demonstrated that 
the expression of PD-L1 is upregulated in mice models 
following exposure to BCG, therefore lending to a theo-
retical synchronous relationship between the two agents 
and providing further grounds for investigation into 
this combination therapy.17–19 Several investigations 
are currently underway assessing the potential benefits 
of pembrolizumab. NCT02808143, a phase I clinical 
trial, assessing the safety and efficacy of intravesicular 
pembrolizumab and BCG, in a similar cohort of patients 
as in the present study, is underway. Notably, the route 
of administration between the two studies differs, as in 
our investigation, pembrolizumab is administered intra-
venously, whereas in NCT02808143, pembrolizumab is 
administered intravesically. However, despite these differ-
ences, it is essential that multiple studies at various institu-
tions be performed to determine the optimal scheduling, 
dose and route of administration, especially in the early 
investigations of newer agents.
This potential benefit of pembrolizumab is being 
assessed beyond patients limited to NMIBC. Of note, 
pembrolizumab is being investigated in patients who 
have developed metastatic urothelial cell carcinoma, in 
combination with other agents or those with muscle-in-
vasive disease.20 A phase III randomised clinical trial, 
currently being carried out by Fradet et al, NCT02256436, 
is seeking to determine the potential benefit of receiving 
pembrolizumab versus paclitaxel, docetaxel or vinflunine 
in patients who have metastatic, locally advanced or unre-
sectable urothelial cell carcinoma following recurrence 
or progression after treatment with platinum-containing 
chemotherapy. Recent findings from the aforementioned 
investigation have demonstrated a significant increase in 
overall survival in those treated with pembrolizumab. It 
was also noted that the rate of treatment-related AEs was 
lower in those who received pembrolizumab, 62.0% than 
those who received chemotherapy, 90.6%.20 21 Other inves-
tigations, such as NCT02621151, are currently assessing 
the combination of concurrent pembrolizumab, chemo-
therapy and radiation therapy in patients with muscle 
invasive bladder cancer who are also not deemed surgical 
candidates. The potential vast utility of pembrolizumab is 
encouraging.
Ultimately, if the combination of pembrolizumab and 
BCG is to yield promising results, it would provide patients 
with an alternative to radical cystectomy and potentially 
change the standard of care.
Contributors SA, KRo, KRa and SS conceived the idea and the methodology for 
this clinical trial. The manuscript was drafted and revised by MLJ, MD, AS and SA. 
All authors read and approved the final manuscript.
funding This investigator-initiated trial is financially sponsored by Merck & Co.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with 
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on different terms, 
provided the original work is properly cited, appropriate credit is given, 
any changes made indicated, and the use is non-commercial. See: http:// 
creativecommons. org/ licenses/ by- nc/ 4. 0/.
copyright.
 o
n
 D
ecem
ber 6, 2019 at Henry Ford Hospital. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028287 on 17 July 2019. Downloaded from 
9Jamil ML, et al. BMJ Open 2019;9:e028287. doi:10.1136/bmjopen-2018-028287
Open access
rEfErEnCEs
 1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA 
Cancer J Clin 2003;53:5–26.
 2. Herr HW, Badalament RA, Amato DA, et al. Superficial bladder 
cancer treated with bacillus Calmette-Guerin: a multivariate analysis 
of factors affecting tumor progression. J Urol 1989;141:22–8.
 3. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 
1995;153(3 Pt 1):564–72.
 4. Lavallée LT, Schramm D, Witiuk K, et al. Peri-operative morbidity 
associated with radical cystectomy in a multicenter database of 
community and academic hospitals. PLoS One 2014;9:e111281.
 5. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-
PD-L1 antibody in patients with advanced cancer. N Engl J Med 
2012;366:2455–65.
 6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and 
immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 
2012;366:2443–54.
 7. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression 
by urothelial carcinoma of the bladder and BCG-induced 
granulomata: associations with localized stage progression. Cancer 
2007;109:1499–505.
 8. Vegt PD, Witjes JA, Witjes WP, et al. A randomized study of 
intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus 
Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and 
carcinoma in situ of the bladder. J Urol 1995;153(3 Pt 2):929–33.
 9. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in 
tolerance and immunity. Annu Rev Immunol 2008;26:677–704.
 10. Zhang P, Su DM, Liang M, et al. Chemopreventive agents induce 
programmed death-1-ligand 1 (PD-L1) surface expression in breast 
cancer cells and promote PD-L1-mediated T cell apoptosis. Mol 
Immunol 2008;45:1470–6.
 11. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on 
non-small cell lung cancer cells and its relationship with tumor-
infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 
2004;10:5094–100.
 12. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 
in renal cell carcinoma patients: Indicator of tumor aggressiveness 
and potential therapeutic target. Proc Natl Acad Sci U S A 
2004;101:17174–9.
 13. De Libero G, Mori L. The T-cell response to lipid antigens of 
mycobacterium tuberculosis. Front Immunol 2014;5:219.
 14. Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: Phase II 
trial of intravesical gemcitabine in patients with nonmuscle invasive 
bladder cancer and recurrence after 2 prior courses of intravesical 
bacillus Calmette-Guérin. J Urol 2013;190:1200–4.
 15. Khan I, Sarker SJ, Hackshaw A. Smaller sample sizes for phase 
II trials based on exact tests with actual error rates by trading-
off their nominal levels of significance and power. Br J Cancer 
2012;107:1801–9.
 16. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: 
defining standard protocol items for clinical trials. Ann Intern Med 
2013;158:200–7.
 17. Chevalier MF, Schneider AK, Cesson V, et al. Conventional and PD-
L1-expressing Regulatory T Cells are Enriched During BCG Therapy 
and may Limit its Efficacy. Eur Urol 2018;74:540–4.
 18. Hashizume A, Umemoto S, Yokose T, et al. Enhanced expression of 
PD-L1 in non-muscle-invasive bladder cancer after treatment with 
Bacillus Calmette-Guerin. Oncotarget 2018;9:34066–78.
 19. Wang Y, Liu J, Yang X, et al. Bacillus Calmette-Guérin and anti-PD-L1 
combination therapy boosts immune response against bladder 
cancer. Onco Targets Ther 2018;11:2891–9.
 20. Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of 
PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. 
Cancer Treat Rev 2017;54:58–67.
 21. Fradet Y, Bellmunt J, De Wit R, et al. Pembrolizumab (pembro) versus 
investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, 
advanced urothelial cancer (UC): 2-year follow-up from the phase 
3 KEYNOTE-045 trial. Journal of Clinical Oncology 2018;36(15_
suppl):4521.
copyright.
 o
n
 D
ecem
ber 6, 2019 at Henry Ford Hospital. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028287 on 17 July 2019. Downloaded from 
